Effects of an oral GH [growth hormone] secretagogue (MK-677) [Ibutamoren] on body composition and functional ability of older adults
Phase of Trial: Phase I/II
Latest Information Update: 30 Jul 2007
At a glance
- Drugs Ibutamoren (Primary)
- Indications Alzheimer's disease; Fibromyalgia; Fracture; Muscular atrophy; Postmenopausal osteoporosis; Somatotropin deficiency
- Focus Pharmacodynamics
- Acronyms MOT089
- 31 Aug 2018 Biomarkers information updated
- 30 Jul 2007 The expected completion date for this trial is now 1 Jun 2004.
- 20 Jul 2007 New trial record.